Suchergebnisse - "Gupta, Neeraj"

PubPharm (21)

1

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors : characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

2

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

3

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

4

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

5

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2018

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

6

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

7

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

8

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

9

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma : China Continuation study

enthalten in: Journal of hematology & oncology | 2017

von Hou, J. | Jin, J. | Xu, Y. | +18

10

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

enthalten in: Journal of hematology & oncology | 2017

von Hou, J. | Jin, J. | Xu, Y. | +18